Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CINJ 050705: OAM4224g: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-MET, Administered Intravenously in Patients with Locally Advanced or Metastatic Solid Tumours.

Trial Profile

CINJ 050705: OAM4224g: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-MET, Administered Intravenously in Patients with Locally Advanced or Metastatic Solid Tumours.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Onartuzumab (Primary) ; Bevacizumab
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 02 Apr 2011 Final results presented at AACR 2011.
    • 18 Feb 2010 Planned initiation date (1 Aug 2007), actual number of patients (44), lead trial investigator (Patel P) and investigational drug (bevacizumab) identified as reported by ClinicalTrials.gov record.
    • 18 Feb 2010 New source identified and integrated (ClinicalTrials.gov record; NCT01068977)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top